Filtered By:
Cancer: Lung Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 264 results found since Jan 2013.
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
CONCLUSION: Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.PMID:37700573 | DOI:10.1177/10600280231197459
Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Natalie Mausey Zachery Halford Source Type: research
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial using real-world data
This study replicated the atezolizumab and docetaxel arms of the OAK trial using RWD and compared progression-free survival (PFS) outcomes derived from abstracted physician's notes in RWD (rwPFS) against PFS outcomes derived from the clinical trial (ctPFS). Atezolizumab and docetaxel arms of the phase III OAK RCT (NCT02008227) were replicated in a US nationwide real-world database using selected OAK inclusion/exclusion criteria and propensity score-based adjustment for baseline prognostic variables. Concordance of outcomes was assessed using Kaplan-Meier (KM) medians and hazard ratios (HRs). The RWD cohorts comprised 133 a...
Source: Clinical Pharmacology and Therapeutics - September 11, 2023 Category: Drugs & Pharmacology Authors: Shivani K Mhatre Robson J M Machado Thanh G N Ton Huong Trinh Julien Mazieres Achim Rittmeyer Michael T Bretscher Source Type: research
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
CONCLUSIONS: Although ICI plus PBC likely resulted in superior survival outcomes compared to ICI treatment alone, it did increase toxicity. Cemiplimab presented a well-balanced efficacy and safety profile in advanced NSCLC treatment. Our findings with the current ICIs comparisons will aid future trials for cancer immunotherapy.REGISTRATION: PROSPERO, https://www.crd.york.ac.uk/PROSPERO/, CRD42022323879.PMID:37596898 | DOI:10.1097/CM9.0000000000002750
Source: Chinese Medical Journal - August 19, 2023 Category: General Medicine Authors: Yan Li Xueyan Liang Huijuan Li Xiaoyu Chen Source Type: research
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
CONCLUSION: Given the limited real-world efficacy on EGFR-mutant NSCLC resistant to osimertinib and platinum-based chemotherapy, the development of more highly potent post-treatment therapies is warranted.PMID:37572265 | DOI:10.1007/s12325-023-02616-9
Source: Adv Data - August 12, 2023 Category: Epidemiology Authors: Hidetoshi Hayashi Makoto Nishio Michiko Takahashi Hiroaki Tsuchiya Mami Kasahara-Kiritani Source Type: research
Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of
Operable Stage III NSCLC
CONCLUSIONS: Camrelizumab combined with Docetaxel and Cisplatin can be used as a new adjuvant treatment for operable stage III NSCLC. Through the observation and control of AEs, treatment measures can be taken in time to reduce further complications, ensure patient' safety, and ensure the authenticity, scientificity and reliability of clinical trial data.PMID:37488083 | DOI:10.3779/j.issn.1009-3419.2023.102.23
Source: Cancer Control - July 24, 2023 Category: Cancer & Oncology Authors: Yun Zhang Shuang Zhou Wentao Tao Rong Li Source Type: research
RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors
J Control Release. 2023 Jun 23:S0168-3659(23)00406-6. doi: 10.1016/j.jconrel.2023.06.032. Online ahead of print.ABSTRACTNanomedicines while showing a great potential in improving the performance of chemotherapeutics like docetaxel (DTX) are distressed by a high liver deposition and poor tumor penetration, which might not only cause liver toxicity but also moderate therapeutic effect. Herein, we report that cRGD-directed 24 nm disulfide-crosslinked micellar docetaxel (cRGD-MDTX) presents low liver accumulation, high tumor uptake, and deep tumor penetration, leading to potent suppression of different solid tumors. cRGD-MDTX ...
Source: Cancer Control - June 25, 2023 Category: Cancer & Oncology Authors: Wencheng Yan Beibei Guo Zhe Wang Jiangtao Yang Zhiyuan Zhong Fenghua Meng Source Type: research
Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy
Biomed Pharmacother. 2023 Jun 15;165:115023. doi: 10.1016/j.biopha.2023.115023. Online ahead of print.ABSTRACTDual-receptor targeted (DRT) nanoparticles which contain two distinct targeting agents may exhibit higher cell selectivity, cellular uptake, and cytotoxicity toward cancer cells than single-ligand targeted nanoparticle systems without additional functionality. The purpose of this study is to prepare DRT poly(lactic-co-glycolic acid) (PLGA) nanoparticles for targeting the delivery of docetaxel (DTX) to the EGFR and PD-L1 receptor positive cancer cells such as human glioblastoma multiform (U87-MG) and human non-small...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 17, 2023 Category: Drugs & Pharmacology Authors: Fakhrossadat Emami Ramesh Duwa Asmita Banstola Seon Min Woo Taeg Kyu Kwon Simmyung Yook Source Type: research
Meta-Analysis of Atezolizumab vs Docetaxel in Non-Small Cell Lung Cancer Treatment Outcomes
CONCLUSION: Compared with docetaxel, atezolizumab can significantly prolong OS in patients with NSCLC and reduce the occurrence of TRAEs, but there is no advantage in PFS or ORR remission rate. Due to some limitations in case numbers and quality of included studies, multicenter, large sample, high-quality RCTs are still needed for further validation.PMID:37318886
Source: Alternative Therapies in Health and Medicine - June 15, 2023 Category: Complementary Medicine Authors: Yingya Fu Guojuan Xue Source Type: research
